STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLMT
  4. [Form 4] Calumet, Inc. Insider Trading Activity

Calumet (CLMT) Form 4 Shows 2.9k RSUs Awarded to Director Mawer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Calumet, Inc. (CLMT) Form 4 reports that director Stephen P. Mawer was granted a total of 2,954 restricted stock units (RSUs) on 08/05/2025 at an exercise price of $0.

The award is split into (i) 2,216 fully-vested RSUs that will settle upon the earlier of a date selected by the director or his termination, and (ii) 738 RSUs issued through the company’s Deferred Compensation Plan that vest 25 % each July 1 beginning 07/01/2026. Each RSU is economically equivalent to one share of Calumet common stock.

After the grant, Mawer directly holds 2,954 derivative securities convertible into common shares; no open-market purchases or sales were disclosed. The filing reflects routine equity compensation, strengthens management-shareholder alignment, and introduces only minor prospective dilution with no immediate impact on earnings or cash flow.

Positive

  • Enhanced alignment: Grant of 2,954 RSUs ties director compensation to shareholder value.

Negative

  • Future dilution: Conversion of RSUs will incrementally increase the share count.

Insights

TL;DR: 2,954 RSUs granted to director; neutral impact—aligns incentives with minimal dilution risk.

The Form 4 shows a standard equity grant rather than a purchase or sale, so it does not signal insider sentiment about valuation. Fully-vested RSUs (2,216) offer immediate ownership potential, while the deferred tranche (738) spreads vesting over four years, promoting long-term engagement. Because the units convert on a one-for-one basis, the maximum future share issuance is limited to 2,954 shares—immaterial relative to Calumet’s typical market float. No cash outlay, strike price, or performance hurdles are involved, so shareholder cost is strictly dilutionary. Overall, the transaction is routine board compensation and should have negligible valuation impact.

Insider Mawer Stephen P
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 2,216 $0.00 --
Grant/Award Restricted Stock Units 738 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 2,216 shares (Direct); Restricted Stock Units — 738 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit is the economic equivalent of one share of Calumet, Inc. common stock, par value $0.01 per share. Each Restricted Stock Unit will become settled upon the earlier of the date specified by the reporting person or the reporting person's termination date. Restricted Stock Units are 100% vested. Each Restricted Stock Unit will be settled upon the earlier of the date specified by the reporting person or the reporting person's termination date pursuant to the Deferred Compensation Plan. 25% of the Restricted Stock Units vest on July 1 of each year beginning on July 1, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mawer Stephen P
(Last) (First) (Middle)
1060 N CAPITOL AVE
SUITE 6-401
(Street)
INDIANAPOLIS IN 46204
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Calumet, Inc. /DE [ CLMT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 08/05/2025 A 2,216 (2) (2) Common Stock, par value $0.01 per share 2,216 $0 2,216 D
Restricted Stock Units (1) 08/05/2025 A 738 (3) (3) Common Stock, par value $0.01 per share 738 $0 738 D
Explanation of Responses:
1. Each Restricted Stock Unit is the economic equivalent of one share of Calumet, Inc. common stock, par value $0.01 per share.
2. Each Restricted Stock Unit will become settled upon the earlier of the date specified by the reporting person or the reporting person's termination date. Restricted Stock Units are 100% vested.
3. Each Restricted Stock Unit will be settled upon the earlier of the date specified by the reporting person or the reporting person's termination date pursuant to the Deferred Compensation Plan. 25% of the Restricted Stock Units vest on July 1 of each year beginning on July 1, 2026.
/s/ Connor J. Egan, as attorney-in-fact 08/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many RSUs did Calumet (CLMT) grant to Stephen P. Mawer?

2,954 RSUs were granted—2,216 fully vested and 738 deferred.

When do the deferred RSUs begin to vest?

The 738 deferred RSUs begin vesting 25 % each year on July 1, 2026.

What is the cost basis of the RSU grant?

The RSUs were granted at $0 exercise price; they are equity awards, not purchases.

Does the filing indicate any insider buying or selling of Calumet stock?

No. The Form 4 only reports an equity grant; there were no open-market transactions.

Will the RSU grant immediately dilute existing shareholders?

No immediate dilution occurs; dilution happens only upon settlement when RSUs convert to common shares.